IDEAS home Printed from https://ideas.repec.org/p/osf/socarx/vbxzs.html
   My bibliography  Save this paper

Investigación y Desarrollo (I+D) en el Sector Farmacéutico: avances, limitaciones, selectividad y negligencia

Author

Listed:
  • Stacciarini, João Henrique Santana

    (Federal University of Goiás)

Abstract

Con el objetivo de contribuir a los estudios y debates sobre el proceso de Investigación y Desarrollo (I+D) en el sector farmacéutico, este trabajo realizó una extensa recolección, organización y análisis de datos sobre el tema, explorando los avances, limitaciones, selectividad y negligencia en este ámbito. Se reveló que el sector farmacéutico representa el segundo mayor inversor en I+D, registrando un gasto global de 238 mil millones de dólares en 2021. La búsqueda de ganancias derivadas de medicamentos exitosos motivó un crecimiento significativo en el número de empresas farmacéuticas centradas en I+D, resultando en 5.416 corporaciones que prueban más de 20 mil fármacos en diversas fases de investigación y desarrollo. Sin embargo, este estudio también señala las limitaciones de los productos derivados de la I+D farmacéutica, observando que muchos medicamentos recién aprobados no presentan ventajas significativas sobre los ya existentes y tienden a priorizar el mantenimiento de franquicias rentables o la competencia en el mercado, en detrimento del bienestar de la población. Además, se destaca la selectividad y negligencia en las inversiones en I+D, con ciertas enfermedades recibiendo mayor atención debido a una variedad de intereses, incluyendo aspectos socioeconómicos.

Suggested Citation

  • Stacciarini, João Henrique Santana, 2025. "Investigación y Desarrollo (I+D) en el Sector Farmacéutico: avances, limitaciones, selectividad y negligencia," SocArXiv vbxzs, Center for Open Science.
    • Handle: RePEc:osf:socarx:vbxzs
    DOI: 10.31219/osf.io/vbxzs
    as

    Download full text from publisher

    File URL: https://osf.io/download/6783df9e11969c7c82428548/
    Download Restriction: no
    File URL: https://libkey.io/10.31219/osf.io/vbxzs?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W., 2016. "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, Elsevier, vol. 47(C), pages 20-33.
    2. Franco Malerba & Luigi Orsenigo, 2015. "The evolution of the pharmaceutical industry," Business History, Taylor & Francis Journals, vol. 57(5), pages 664-687, July.
    3. XIONG ,Zhiyue & GU, Minghua & ZHOU ,Wei & LIU ,Yongxian & XIA, Tingting & NONG ,Mengling & LI ,Xinsheng & LI, Yimiao & LIANG ,Jie & HE, Lishan, 2022. "Research on the Development of Rural E-commerce in China," Asian Agricultural Research, USA-China Science and Culture Media Corporation, vol. 14(07), July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Stacciarini, João Henrique Santana, 2025. "Investigación y Desarrollo (I+D) en el Sector Farmacéutico: avances, limitaciones, selectividad y negligencia," SocArXiv vbxzs_v1, Center for Open Science.
    2. Angelo Kenneth S. Romasanta & Peter Sijde & Jacqueline Muijlwijk-Koezen, 2020. "Innovation in pharmaceutical R&D: mapping the research landscape," Scientometrics, Springer;Akadémiai Kiadó, vol. 125(3), pages 1801-1832, December.
    3. Camille Loir & Bertrand Groslambert, 2023. "The impact of innovation on the profitability of the biotech industry," Economics Bulletin, AccessEcon, vol. 43(3), pages 1286-1297.
    4. Ute Laermann-Nguyen & Martin Backfisch, 2021. "Innovation crisis in the pharmaceutical industry? A survey," SN Business & Economics, Springer, vol. 1(12), pages 1-37, December.
    5. Gergő Tömöri & Vilmos Lakatos & Bernadett Béresné Mártha, 2021. "The Effect of Financial Risk Taking on Profitability in the Pharmaceutical Industry," Economies, MDPI, vol. 9(4), pages 1-14, October.
    6. Pooja Thakur-Wernz & Olga Bruyaka, 2017. "Co-evolutionary Perspective on Sourcing Portfolios: Examining Sourcing Choices for Clinical Trials of Bio-pharmaceutical Firms," Management International Review, Springer, vol. 57(6), pages 909-946, December.
    7. Dosis, Anastasios & Muthoo, Abhinay, 2019. "Experimentation in Dynamic R&D Competition," CRETA Online Discussion Paper Series 52, Centre for Research in Economic Theory and its Applications CRETA.
    8. Yusuke Oh & Koji Takahashi, 2020. "R&D and Innovation: Evidence from Patent Data," Bank of Japan Working Paper Series 20-E-7, Bank of Japan.
    9. Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
    10. Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022. "Generic competition and the incentives for early-stage pharmaceutical innovation," Research Policy, Elsevier, vol. 51(10).
    11. Patricia Laurens & Christian Le Bas & Antoine Schoen, 2019. "Worldwide IP coverage of patented inventions in large pharma firms: to what extent do the internationalisation of R&D and firm strategy matter?," Post-Print hal-01725229, HAL.
    12. Unsal, Omer & Houston, Reza, 2024. "R&D grants and medical innovation," Journal of Economics and Business, Elsevier, vol. 128(C).
    13. Abe C. Dunn & Lasanthi Fernando & Eli Liebman, 2024. "How Much Are Medical Innovations Worth? A Detailed Analysis Using Cost-Effectiveness Studies," BEA Papers 0132, Bureau of Economic Analysis.
    14. Alfred B. Ordman, 2022. "When Will the FDA Do What Is in People’s Best Interests?," American Journal of Economics and Sociology, Wiley Blackwell, vol. 81(4), pages 721-751, September.
    15. Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Risks, MDPI, vol. 6(3), pages 1-27, July.
    16. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
    17. Hao Tan, 2017. "Making impact through industry-focused research: An Asia Pacific perspective," Asia Pacific Journal of Management, Springer, vol. 34(3), pages 487-503, September.
    18. Fabian Gaessler & Stefan Wagner, 2022. "Patents, Data Exclusivity, and the Development of New Drugs," The Review of Economics and Statistics, MIT Press, vol. 104(3), pages 571-586, May.
    19. Yixiang Ruan & Chenyin Lu & Ning Xu & Yuchen He & Yixin Chen & Jian Zhang & Jun Xuan & Jianzhang Pan & Qun Fang & Hanyu Gao & Xiaodong Shen & Ning Ye & Qiang Zhang & Yiming Mo, 2024. "An automatic end-to-end chemical synthesis development platform powered by large language models," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    20. Gregor Dorfleitner & Felix Rößle, 2018. "The financial performance of the health care industry: a global, regional and industry specific empirical investigation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 585-594, May.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:osf:socarx:vbxzs. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: OSF (email available below). General contact details of provider: https://arabixiv.org .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.